Jazz Pharma CMO on GEA Data, Pipeline with Bloomberg Intelligence and Leerink
Join Bloomberg Intelligence equity analyst Ann-Hunter van Kirk for a conversation with Robert Iannone, head of R&D and CMO of Jazz Pharmaceuticals and Leerink equity analysts Marc Goodman and Andrew Berens ahead of upcoming zanidatamab data in GEA. We'll also discuss the anticipated Zepzelca 1L ES-SCLC sNDA and more about Jazz's pipeline.